Rosumac-F is an oral treatment option sometimes prescribed for individuals managing abnormal lipid levels in the blood, such as dyslipidemia or combined hyperlipidemia.

The combination of rosuvastatin and fenofibrate is used for patients with mixed dyslipidemia who are working to manage high LDL-C and elevated triglycerides, especially when combined with a need to address low HDL-C. The treatment is applied in the management of conditions such as primary hypercholesterolemia, mixed dyslipidemia, or combined hyperlipidemia.

Managing the components of the lipid profile often requires a comprehensive strategy for individuals with complex lipid abnormalities. The medication supports the overall management of these lipid factors, which is part of reducing potential health risks associated with uncontrolled levels.

Quick Fact: Management of Elevated Blood Lipids (Rosumac-F may support the maintenance of a healthy lipid profile, including LDL-C and triglycerides, as part of an overall treatment plan.)

This medicine is an adult-only combination treatment and is contraindicated for several specific patient groups to prevent serious health risks. Use is not recommended in children and adolescents under 18 years of age due to lack of established safety and effectiveness.

Who Should NOT Take This Medicine (Contraindicated Populations)

• Pregnancy and Breastfeeding: Use is prohibited during pregnancy and in women who are breastfeeding or may become pregnant, as it may cause harm to the fetus or infant.
• Severe Organ Impairment: Patients with active liver disease, including unexplained, persistent liver enzyme elevations, or those with severe kidney impairment (renal failure).
• Allergy: Individuals with a known hypersensitivity to rosuvastatin, fenofibrate, or any of the product components.
• Myopathy: Patients with an existing muscle disease (myopathy).
• Specific Drug Interactions: Patients currently taking the immunosuppressant ciclosporin or the antiviral combination sofosbuvir/velpatasvir/voxilaprevir.

Use Requires Caution and Special Consideration

Caution is advised and closer medical supervision is necessary for older patients (e.g., over 70 years old), patients with mild to moderate kidney problems, mild to moderate liver impairment, or those with a history of gallbladder disease. Patients with predisposing factors for muscle breakdown, such as inadequately treated hypothyroidism or a personal or family history of muscular disorders, require careful monitoring.

Interactions with other medicines and products

The regulatory documentation for Rosumac-F outlines specific constraints and requirements when co-administering the medicine with other medicinal products, supplements, or substances.

Interaction Classifications

Co-administration with certain substances is classified as contraindicated. This applies to the use of Gemfibrozil due to the officially documented risk of a significant increase in rosuvastatin systemic exposure. Similarly, Cyclosporine use is strictly restricted or contraindicated because it inhibits drug transporters, causing a substantial rise in rosuvastatin plasma concentration. Drugs that inhibit these transporters, such as certain Antivirals, are also noted to increase rosuvastatin exposure.

Pharmacodynamic Constraints

A pharmacodynamic interaction with Coumarin Anticoagulants (e.g., Warfarin) is documented, requiring mandated frequent monitoring of the International Normalized Ratio (INR) due to the increased risk of bleeding. Other agents known to increase the risk of muscle toxicity, such as high-dose Niacin, are noted for their additive effect.

Timing and Substance Constraints

Specific timing separation rules are required to maintain efficacy: Aluminum and Magnesium Hydroxide Antacids must be administered at least two hours after Rosumac-F to prevent reduced absorption. Official documents also note that products containing Red Yeast Rice or consumption of Alcohol may compound the risk of liver or muscle toxicity.

Population-Specific Notes

The risk of interaction is explicitly noted to be heightened in patients with Severe Renal Impairment, where the active fenofibrate metabolite may accumulate due to reduced clearance.

How Rosumac-F Works: Dual Mechanism of Action

The pharmacodynamic activity of Rosumac-F results from the simultaneous action of its two components, targeting separate yet complementary pathways of lipid metabolism within the liver.

---

Cholesterol Synthesis Blockade and LDL Clearance

This mechanistic domain is governed by Rosuvastatin, which functions as a competitive inhibitor of the enzyme HMG-CoA reductase. By blocking the rate-limiting step of cholesterol production in liver cells, the resulting biological feedback loop forces the liver to massively upregulate its Low-Density Lipoprotein (LDL) Receptors on the cell surface. This molecular cascade results in the physiological consequence of increased clearance and removal of LDL cholesterol from the circulating bloodstream.

---

PPAR(alpha) Agonism and Triglyceride Catabolism

The second mechanistic domain is defined by the Fenofibrate component, which acts as a ligand and agonist for the Peroxisome Proliferator-Activated Receptor alpha (PPARalpha) nuclear receptor. Activation of PPARalpha genetically modulates the expression of key metabolic proteins, notably Lipoprotein Lipase (LPL). This process enhances the biological pathway responsible for the hydrolysis and breakdown of triglyceride-rich lipoproteins (VLDL), resulting in the physiological consequence of reduced triglycerides and an increase in HDL particles.

Rosumac-F is a fixed-dose combination (FDC) medicine taken orally as a film-coated tablet, intended for maintenance therapy. Treatment with this combination is initiated after a patient's individual monocomponent doses (Rosuvastatin and Fenofibrate) have been established.

The standard adult dose is one tablet once daily. It is generally advised to take the tablet at the same time each day for consistency. The tablet must be swallowed whole with water and must not be crushed, dissolved, or chewed. This medication may be taken with or without food.

Administration Constraint	Instruction
Missed Dose	Skip the forgotten dose and resume the schedule the next day; do not take two doses.
Timing with Sequestrants	Separate the FDC by at least 2 hours before or 4 hours after a bile acid sequestrant.

Dose selection accounts for component-specific rules, such as those concerning renal function and ancestry. For patients with moderate renal impairment (creatinine clearance <60 mL/min) or those of Asian ancestry, the rosuvastatin component dose is typically limited to a maximum of 10 mg once daily. A lower component dose (e.g., 5 mg) is also recommended when selecting the FDC strength for patients over 70 years of age.

Research Evidence / Overview of Studies for Rosumac-F

---

Evidence for Dual Modification in Mixed Dyslipidemia

Research has explored the evaluation of Rosumac-F in patients with mixed dyslipidemia, a condition where individuals have elevated levels of both cholesterol (LDL-C) and triglycerides (TG). The primary evidence comes from Randomized Controlled Trials (RCTs) and systematic reviews. These studies were used in research exploring how blood fat levels change over defined time intervals.

The research examined changes in key lipid outcomes related to systemic or functional imbalance. Findings describe patterns observed in the studies, where the combination was studied to monitor measured levels of LDL-C and Triglycerides. However, reported outcomes were typically derived from study periods of approximately 12 weeks, meaning the reported outcomes reflect short-term changes in lipid biomarkers, not long-term health outcomes.

The evidence contributes to understanding short-term changes in lipid patterns, but long-term outcomes are not fully established based solely on these short-term studies. Further, research provides context but not individual predictions, as findings describe group patterns, not personal outcomes.

---

Research for High-Risk Adult Populations

Specific research has explored the evaluation of Rosumac-F in adults who are part of high-risk cohorts (for cardiovascular events), particularly those with conditions associated with acute or disruptive episodes, such as established Coronary Artery Disease (CAD), or those with comorbidities like Type 2 Diabetes Mellitus. Studies monitored patients in research exploring short-term changes and tracking the evolution of lipid outcomes.

In these high-risk cohorts, trials focused on patients who were already stabilized on the individual components (Rosuvastatin and Fenofibrate) and examined the measured outcomes following a switch to the FDC. Outcomes related to systemic imbalance were observed in these studies. For instance, some intermediate-term research explored physical changes in the arteries, such as examining coronary atherosclerotic plaque volume over approximately a one-year period.

---

Long-Term Data and Follow-up Periods

The majority of core efficacy research for Rosumac-F utilized follow-up durations that were limited to the short term, often around 12 weeks. This length of time provides insight into the initial measured change in lipid biomarkers.

There is limited information for long-term outcomes. While studies contribute to the broader evidence landscape by showing what has been observed so far, evidence exploring the durability of the lipid-level patterns over many years is not fully established specifically for the FDC. Long-term effects are not fully established; while the monotherapy components have decades of data, the specific long-term profile of the Rosumac-F combination remains to be characterized.

Key Studies & References

1. Comparison of the lipid-modifying efficacy of rosuvastatin/fenofibrate fixed-dose combination versus monotherapy in patients with mixed dyslipidemia

Common questions about Rosumac-F (FAQ)

---

Q: Can Rosumac-F be taken with multivitamins or supplements?

Official guidance typically advises caution when taking any supplements or complementary medicines with prescription drugs, as specific interactions may not be fully documented. The official product information explicitly mentions known interactions with high-dose Niacin and products containing Red Yeast Rice. Official product information emphasizes that any new supplements are best reviewed by a healthcare provider.

---

Q: Is there a link between Rosumac-F and changes in blood sugar?

Studies based on the statin component indicate that increases in HbA1 c and fasting serum glucose have been reported in the class of medicines known as statins. In some cases, these changes may be significant enough to exceed the diagnostic threshold for diabetes mellitus. Official regulatory documents include this metabolic effect in the safety information.

---

Q: What if Rosumac-F doesn't seem to be working for me?

The medicine's efficacy is typically measured by specific lab tests (lipid panels) ordered by a healthcare provider. Regulatory guidance indicates that if target lipid levels are not achieved, a medical professional may permit dose adjustment after a defined time period, often around four weeks. The response to the medicine is assessed based on these individual test results.

---

Q: Are there any known interactions between Rosumac-F and grapefruit juice?

According to official product information, the rosuvastatin component is not extensively processed by the CYP3A4 liver enzyme, which is the enzyme responsible for the well-known grapefruit juice interaction with certain other statins. Therefore, this medicine typically does not carry the same specific warning regarding grapefruit consumption as those other statin medicines.

---

Q: What is the difference between Rosumac and Rosumac-F?

Rosumac-F is a Fixed-Dose Combination (FDC) medicine, containing both Rosuvastatin and Fenofibrate in one tablet. Rosumac is generally the brand name for the monotherapy product, containing only Rosuvastatin. The 'F' in Rosumac-F signifies the addition of the Fibrate component, allowing for a dual-action approach to managing blood fats.

---

Q: Does Rosumac-F help with weight loss?

No. The official regulatory purpose of Rosumac-F is strictly defined as dual lipid modification for the management of high blood fats, specifically elevated cholesterol and triglycerides. It is not approved or indicated for use as a medication for weight reduction.

---

Q: What happens when you stop taking Rosumac-F?

Rosumac-F is prescribed as a maintenance therapy intended for long-term use. If treatment is discontinued, official information states that cholesterol and triglyceride levels typically return to pre-treatment levels over a period of weeks to months.

---

Q: Is Rosumac-F considered a 'high-intensity' treatment?

The statin component, Rosuvastatin, is generally recognized as part of the high-intensity statin class based on its dose-dependent ability to reduce LDL-C (low-density lipoprotein cholesterol). However, the fixed-dose combination product is primarily categorized by its dual mechanism of action to treat mixed dyslipidemia, utilizing both the statin and fibrate components.

---

Q: What is the half-life of Rosumac-F in the body?

Official pharmacological documents detail the half-life for each active component. The half-life of the Rosuvastatin component is approximately 19 hours. Similarly, the half-life of the active metabolite of the Fenofibrate component is approximately 20 hours.

---

Q: Does taking Rosumac-F affect my ability to drive?

The official product label notes that side effects such as dizziness or fatigue may occur in some patients. If these symptoms are experienced, official documents specify that caution should be exercised and driving or operating heavy machinery should be avoided until symptoms have resolved.

---

Q: How often are the effects of Rosumac-F checked by a doctor?

According to official regulatory guidance, routine monitoring is required while on this medicine. This typically involves performing liver enzyme tests before starting treatment and periodically thereafter. Follow-up lipid panels are also conducted to assess the treatment's ongoing effectiveness.

---

Q: What should I do if I think I'm experiencing a serious side effect from Rosumac-F?

Official patient instructions emphasize the need for immediate reporting of certain symptoms, such as unexplained muscle pain, weakness, or cramps (especially with fever), or signs of a serious allergic reaction, to a healthcare professional. Official documents indicate that immediate medical attention is necessary for symptoms suggestive of a serious adverse reaction, such as a severe liver problem.

---

Q: Does Rosumac-F have generic versions available?

Rosumac-F is a specific brand-name medicine. The two active compounds, Rosuvastatin and Fenofibrate, are individually available as generic medicines. Depending on the region and the status of the combination product’s patent, generic versions of the fixed-dose combination may also be available.

How to Store and Dispose of Rosumac-F

Rosumac-F tablets must be stored according to regulatory requirements to ensure stability and safety.

Storage Conditions

Store the medication at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), and not above 30 C. The product must be protected from light and moisture and kept in the original container with the lid tightly closed. As a safety rule, the medicine must be stored out of the sight and reach of children.

---

Disposal Instructions

Do not use the medicine after the expiration date. Any unused or expired Rosumac-F must be disposed of in accordance with local regulations, often by using a drug take-back program. To protect the environment, do not dispose of the tablets in wastewater (do not flush them down the toilet).